Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
Trial details
- Registry ID
- NCT04811131
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial VitiligoNCT04811131 | ARQT | Phase 2 | Terminated | 2021-08-09Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |